ArticleJournal of endocrinological investigation2016
Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.
Article in Journal of endocrinological investigation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 43 citations in OpenAlex.
- Reliability of calcium-phosphorus (Ca/P) ratio as a new, accurate and inexpensive tool in the diagnosis of some Ca-P disorders.Journal of endocrinological investigation · 2019Trial
- Anthropometric Indices and Markers of Atherothrombotic Risk in Subjects with Primary Hyperparathyroidism.Metabolites · 2026Article
- Effectiveness of Sequential Treatment with Zoledronic Acid Following Discontinuation of Denosumab in Osteoporosis: A Narrative Review.Drug design, development and therapy · 2025Review
- The essential role of combined calcium and vitamin D supplementation in the osteoporosis scenario in italy: Expert opinion paper.Archives of osteoporosis · 2024Review
- Bone Metastases and Health in Prostate Cancer: From Pathophysiology to Clinical Implications.Cancers · 2023Review
- COVID-19 lockdown negatively impacted on adherence to denosumab therapy: incidence of non-traumatic fractures and role of telemedicine.Journal of endocrinological investigation · 2022Article
- Efficacy and Safety of Teriparatide in Beta-Thalassemia Major Associated Osteoporosis: A Real-Life Experience.Calcified tissue international · 2022Article
- Changes in the composition of gut and vaginal microbiota in patients with postmenopausal osteoporosis.Frontiers in immunology · 2022Article
- LINC02381, a sponge of miR-21, weakens osteogenic differentiation of hUC-MSCs through KLF12-mediated Wnt4 transcriptional repression.Journal of bone and mineral metabolism · 2022Article
- Management of Osteoporosis in Men: A Narrative Review.International journal of molecular sciences · 2021Review
- Anxiety Levels Predict Bone Mineral Density in Postmenopausal Women Undergoing Oral Bisphosphonates: A Two-Year Follow-Up.International journal of environmental research and public health · 2021Article
- Efficacy of Denosumab Therapy Following Treatment with Bisphosphonates in Women with Osteoporosis: A Cohort Study.International journal of environmental research and public health · 2021Article
- Testosterone and Bone Health in Men: A Narrative Review.Journal of clinical medicine · 2021Review
- Proton Pump Inhibitors and Fractures in Adults: A Critical Appraisal and Review of the Literature.International journal of endocrinology · 2021Review
- Persistence of Denosumab Therapy among Patients with Osteoporosis.Asian spine journal · 2020Article
- Linc02349 promotes osteogenesis of human umbilical cord-derived stem cells by acting as a competing endogenous RNA for miR-25-3p and miR-33b-5p.Cell proliferation · 2020Article
- Adverse effects of media reports on the treatment of osteoporosis.Journal of endocrinological investigation · 2018Review
- Breathlessness in amyotrophic lateral sclerosis: A case report on the role of osteoporosis in the worsening of respiratory failure.Medicine · 2018Article
- Denosumab or oral bisphosphonates in primary osteoporosis: a "real-life" study.Journal of endocrinological investigation · 2018Article
- The epidemiology of osteoporosis in Italian postmenopausal women according to the National Bone Health Alliance (NBHA) diagnostic criteria: a multicenter cohort study.Journal of endocrinological investigation · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 16 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of osteoporosis is aimed to prevent fragility fractures and to stabilize or increase bone mineral density. Several drugs with different efficacy and safety profiles are available. The long-term therapeutic strategy should be planned, and the initial treatment should be selected according to the individual site-specific fracture risk and the need to give the maximal protection when the fracture risk is highest (i.e. in the late life). The present consensus focused on the strategies for the treatment of postmenopausal osteoporosis taking into consideration all the drugs available for this purpose. A short revision of the literature about treatment of secondary osteoporosis due both to androgen deprivation therapy for prostate cancer and to aromatase inhibitors for breast cancer was also performed. Also premenopausal females and males with osteoporosis are frequently seen in endocrine settings. Finally particular attention was paid to the tailoring of treatment as well as to its duration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.